Compare SOTK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | ALXO |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 68.3M |
| IPO Year | 1995 | 2020 |
| Metric | SOTK | ALXO |
|---|---|---|
| Price | $4.09 | $2.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $3.42 |
| AVG Volume (30 Days) | 24.0K | ★ 893.3K |
| Earning Date | 04-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.02 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,504,381.00 | N/A |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | N/A |
| P/E Ratio | $51.19 | ★ N/A |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $3.23 | $0.41 |
| 52 Week High | $5.15 | $2.66 |
| Indicator | SOTK | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 62.81 |
| Support Level | $4.05 | $1.41 |
| Resistance Level | $4.18 | N/A |
| Average True Range (ATR) | 0.18 | 0.30 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 44.04 | 65.38 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.